GAMAMABS is a startup based in France, most recent round Series-c-plus, 2 tracked investors.
Based in France, GAMAMABS is a startup founded in 2017. Its most recent tracked round is Series-c-plus. Brouky records 2 investors associated with the company.
GAMAMABS is a French biotechnology company developing innovative antibody-drug conjugates (ADCs) for the treatment of cancer. Its lead product, GM-102, targets the tumor-associated antigen AMHR2 for ovarian and other solid tumors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.